The acute effects of cannabidiol on the neural correlates of reward anticipation and feedback in healthy volunteers

Background: Cannabidiol has potential therapeutic benefits for people with psychiatric disorders characterised by reward function impairment. There is existing evidence that cannabidiol may influence some aspects of reward processing. However, it is unknown whether cannabidiol acutely affects brain function underpinning reward anticipation and feedback. Hypotheses: We predicted that cannabidiol would augment brain activity associated with reward anticipation and feedback. Methods: We administered a single 600 mg oral dose of cannabidiol and matched placebo to 23 healthy participants in a double-blind, placebo-controlled, repeated-measures design. We employed the monetary incentive delay task during functional magnetic resonance imaging to assay the neural correlates of reward anticipation and feedback. We conducted whole brain analyses and region-of-interest analyses in pre-specified reward-related brain regions. Results: The monetary incentive delay task elicited expected brain activity during reward anticipation and feedback, including in the insula, caudate, nucleus accumbens, anterior cingulate and orbitofrontal cortex. However, across the whole brain, we did not find any evidence that cannabidiol altered reward-related brain activity. Moreover, our Bayesian analyses showed that activity in our regions-of-interest was similar following cannabidiol and placebo. Additionally, our behavioural measures of motivation for reward did not show a significant difference between cannabidiol and placebo. Discussion: Cannabidiol did not acutely affect the neural correlates of reward anticipation and feedback in healthy participants. Future research should explore the effects of cannabidiol on different components of reward processing, employ different doses and administration regimens, and test its reward-related effects in people with psychiatric disorders.

[1]  G. Baio,et al.  Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. , 2020, The lancet. Psychiatry.

[2]  G. Baio,et al.  Cannabidiol for the treatment of cannabis use disorder: Phase IIa double-blind placebo-controlled randomised adaptive Bayesian dose-finding trial , 2020 .

[3]  J. Rudd,et al.  Fundamental Movement Skill Interventions , 2020 .

[4]  S. Naveed,et al.  The therapeutic role of Cannabidiol in mental health: a systematic review , 2020, Journal of Cannabis Research.

[5]  M. Delgado,et al.  Reward Processing , 2019 .

[6]  Ninon Burgos,et al.  New advances in the Clinica software platform for clinical neuroimaging studies , 2019 .

[7]  Y. Hurd,et al.  Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial. , 2019, The American journal of psychiatry.

[8]  P. Griffiths,et al.  Increasing potency and price of cannabis in Europe, 2006–16 , 2019, Addiction.

[9]  S. O'Sullivan,et al.  A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans , 2018, Front. Pharmacol..

[10]  B. Gidal,et al.  A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects , 2018, CNS Drugs.

[11]  I. McGregor,et al.  Cannabidiol treatment reduces the motivation to self-administer methamphetamine and methamphetamine-primed relapse in rats , 2018, Journal of psychopharmacology.

[12]  J. Roiser,et al.  Neuroscience of apathy and anhedonia: a transdiagnostic approach , 2018, Nature Reviews Neuroscience.

[13]  C. Morgan,et al.  Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco withdrawal , 2018, Addiction.

[14]  M. Yücel,et al.  The anticipation and outcome phases of reward and loss processing: A neuroimaging meta‐analysis of the monetary incentive delay task , 2018, Human brain mapping.

[15]  T. Lovick,et al.  Female psychopharmacology matters! Towards a sex-specific psychopharmacology , 2018, Journal of psychopharmacology.

[16]  J. Manzanares,et al.  Cannabidiol reduces ethanol consumption, motivation and relapse in mice , 2018, Addiction biology.

[17]  P. McGuire,et al.  Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial. , 2017, The American journal of psychiatry.

[18]  S. Laviolette,et al.  Adolescent THC Exposure Causes Enduring Prefrontal Cortical Disruption of GABAergic Inhibition and Dysregulation of Sub-Cortical Dopamine Function , 2017, Scientific Reports.

[19]  James A Bisby,et al.  Cannabis Dampens the Effects of Music in Brain Regions Sensitive to Reward and Emotion , 2017, The international journal of neuropsychopharmacology.

[20]  M. Bloomfield,et al.  The Acute Effects of a Dopamine D3 Receptor Preferring Agonist on Motivation for Cigarettes in Dependent and Occasional Cigarette Smokers , 2017, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[21]  F. Guimarães,et al.  Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life , 2017, Front. Pharmacol..

[22]  M. Haney,et al.  Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. , 2017, Drug and alcohol dependence.

[23]  A. Zuardi,et al.  Even High Doses of Oral Cannabidiol Do Not Cause THC-Like Effects in Humans: Comment on Merrick et al. Cannabis and Cannabinoid Research 2016;1(1):102–112; DOI: 10.1089/can.2015.0004 , 2017, Cannabis and cannabinoid research.

[24]  N. Volkow,et al.  The effects of Δ9-tetrahydrocannabinol on the dopamine system , 2016, Nature.

[25]  K. Berridge,et al.  Liking, wanting, and the incentive-sensitization theory of addiction. , 2016, The American psychologist.

[26]  D. Nutt,et al.  Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis ‘amotivational’ hypotheses , 2016, Psychopharmacology.

[27]  G. Bedi,et al.  Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis , 2016, Neuropsychopharmacology.

[28]  L. Parsons,et al.  Keep off the grass? Cannabis, cognition and addiction , 2016, Nature Reviews Neuroscience.

[29]  J. Merrick,et al.  Identification of Psychoactive Degradants of Cannabidiol in Simulated Gastric and Physiological Fluid , 2016, Cannabis and cannabinoid research.

[30]  M. Goodale,et al.  Equal-magnitude size-weight illusions experienced within and between object categories. , 2016, Journal of vision.

[31]  L. Parsons,et al.  Endocannabinoid signaling in reward and addiction , 2015 .

[32]  P. McGuire,et al.  Cannabinoid Modulation of Functional Connectivity within Regions Processing Attentional Salience , 2015, Neuropsychopharmacology.

[33]  C. Morgan,et al.  Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: A randomised, double-blind, placebo-controlled study in cannabis users , 2015, European Neuropsychopharmacology.

[34]  M. Potenza,et al.  Anticipatory Reward Processing in Addicted Populations: A Focus on the Monetary Incentive Delay Task , 2015, Biological Psychiatry.

[35]  M. Treadway,et al.  Reward processing dysfunction in major depression, bipolar disorder and schizophrenia , 2015, Current opinion in psychiatry.

[36]  S. Machado,et al.  Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa. , 2014, CNS & neurological disorders drug targets.

[37]  A. Okely,et al.  Fundamental Movement Skill Interventions in Youth: A Systematic Review and Meta-analysis , 2013, Pediatrics.

[38]  Michael F. Green,et al.  Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome. , 2013, Journal of psychiatric research.

[39]  G. Panagis,et al.  Cannabidiol inhibits the reward‐facilitating effect of morphine: involvement of 5‐HT1A receptors in the dorsal raphe nucleus , 2013, Addiction biology.

[40]  N. Ramsey,et al.  THC reduces the anticipatory nucleus accumbens response to reward in subjects with a nicotine addiction , 2013, Translational Psychiatry.

[41]  R. Murray,et al.  Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment , 2013, Journal of psychopharmacology.

[42]  P. McGuire,et al.  Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers. , 2012, Current pharmaceutical design.

[43]  M. Hellmich,et al.  Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia , 2012, Translational Psychiatry.

[44]  Rita Z. Goldstein,et al.  Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications , 2011, Nature Reviews Neuroscience.

[45]  N. Ramsey,et al.  Involvement of the endocannabinoid system in reward processing in the human brain , 2011, Psychopharmacology.

[46]  R. Roesler,et al.  Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients , 2011, Neuropsychopharmacology.

[47]  J. Roiser,et al.  Reward and Punishment Processing in Depression , 2010, Biological Psychiatry.

[48]  G. Schafer,et al.  Cannabidiol Attenuates the Appetitive Effects of Δ9-Tetrahydrocannabinol in Humans Smoking Their Chosen Cannabis , 2010, Neuropsychopharmacology.

[49]  R. Murray,et al.  Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology , 2010, Neuropsychopharmacology.

[50]  Y. Hurd,et al.  Cannabidiol, a Nonpsychotropic Component of Cannabis, Inhibits Cue-Induced Heroin Seeking and Normalizes Discrete Mesolimbic Neuronal Disturbances , 2009, The Journal of Neuroscience.

[51]  Jeffrey N. Rouder,et al.  Bayesian t tests for accepting and rejecting the null hypothesis , 2009, Psychonomic bulletin & review.

[52]  M. Jaber,et al.  Environmental Enrichment During Early Stages of Life Reduces the Behavioral, Neurochemical, and Molecular Effects of Cocaine , 2009, Neuropsychopharmacology.

[53]  J. W. Aldridge,et al.  Dissecting components of reward: 'liking', 'wanting', and learning. , 2009, Current opinion in pharmacology.

[54]  P. Fusar-Poli Distinct Effects of D9-tetrahydrocannabinol and Cannabidiol on Neural Activation During Emotional Processing , 2009, European Psychiatry.

[55]  H. Heinze,et al.  Mesolimbic Functional Magnetic Resonance Imaging Activations during Reward Anticipation Correlate with Reward-Related Ventral Striatal Dopamine Release , 2008, The Journal of Neuroscience.

[56]  Brian Knutson,et al.  Anticipatory affect: neural correlates and consequences for choice , 2008, Philosophical Transactions of the Royal Society B: Biological Sciences.

[57]  J. Waltz,et al.  Reward processing in schizophrenia: a deficit in the representation of value. , 2008, Schizophrenia bulletin.

[58]  Brian Knutson,et al.  Neural Responses to Monetary Incentives in Major Depression , 2008, Biological Psychiatry.

[59]  Camelia M. Kuhnen,et al.  Nucleus accumbens activation mediates the influence of reward cues on financial risk taking , 2008, Neuroreport.

[60]  R. Pertwee,et al.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarin , 2008 .

[61]  E. Nestler,et al.  The Mesolimbic Dopamine Reward Circuit in Depression , 2006, Biological Psychiatry.

[62]  Arno Villringer,et al.  Dysfunction of ventral striatal reward prediction in schizophrenia , 2006, NeuroImage.

[63]  S. Kapur,et al.  From dopamine to salience to psychosis—linking biology, pharmacology and phenomenology of psychosis , 2005, Schizophrenia Research.

[64]  E. Russo,et al.  Agonistic Properties of Cannabidiol at 5-HT1a Receptors , 2005, Neurochemical Research.

[65]  R. Mechoulam,et al.  Effect of low doses of Δ9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats , 2004, Psychopharmacology.

[66]  Brian Knutson,et al.  Anticipation of Increasing Monetary Reward Selectively Recruits Nucleus Accumbens , 2001, The Journal of Neuroscience.

[67]  M. Christ,et al.  Acute effects of a single oral dose of carvedilol on cardiac sympathovagal balance in man. , 2001, International journal of clinical pharmacology and therapeutics.

[68]  T. G. Burns,et al.  BOOK AND TEST REVIEW , 2000 .

[69]  Brian Knutson,et al.  FMRI Visualization of Brain Activity during a Monetary Incentive Delay Task , 2000, NeuroImage.

[70]  Environmental enrichment , 1996, Animal Welfare.

[71]  O. Aasland,et al.  Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II. , 1993, Addiction.

[72]  F. Graeff,et al.  Effects of ipsapirone and cannabidiol on human experimental anxiety , 1993, Journal of psychopharmacology.

[73]  S. Snider,et al.  Controlled clinical trial of cannabidiol in Huntington's disease , 1991, Pharmacology Biochemistry and Behavior.

[74]  L. Kozlowski,et al.  The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. , 1991, British journal of addiction.

[75]  D. Jackson,et al.  The effect of cannabidiol, alone and in combination with ethanol, on human performance , 1979, Psychopharmacology.

[76]  D. Pizzagalli,et al.  Blunted neural responses to reward in remitted major depression: A high-density event-related potential study. , 2016, Biological psychiatry. Cognitive neuroscience and neuroimaging.

[77]  Guillermo I Carrillo,et al.  A Controlled Clinical Trial , 2015 .

[78]  Thomas M Seed,et al.  Acute Effects , 2011 .

[79]  T. Insel Rethinking schizophrenia , 2010, Nature.

[80]  S. Haber,et al.  The Reward Circuit: Linking Primate Anatomy and Human Imaging , 2010, Neuropsychopharmacology.

[81]  P. McGuire,et al.  Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. , 2009, Archives of general psychiatry.

[82]  R. Pertwee The diverse CB 1 and CB 2 receptor pharmacology of three plant cannabinoids : D 9-tetrahydrocannabinol , cannabidiol and D 9-tetrahydrocannabivarin , 2007 .

[83]  M. First,et al.  Structured clinical interview for DSM-IV axis II personality disorders : SCID-II , 1997 .